INT9426

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 1992
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 6
Disease Relevance 1.35
Pain Relevance 0.51

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (IGFBP1) extracellular space (IGFBP1) extracellular region (IGFBP1)
IGFBP1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Bioavailability 2 99.82 Very High Very High Very High
aspirin 2 99.26 Very High Very High Very High
antagonist 4 88.68 High High
cINOD 2 82.16 Quite High
agonist 2 65.56 Quite High
headache 3 58.80 Quite High
cytokine 4 5.00 Very Low Very Low Very Low
withdrawal 4 5.00 Very Low Very Low Very Low
Inflammation 3 5.00 Very Low Very Low Very Low
Dismenorea 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Diabetes Mellitus 19 93.28 High High
Starvation 1 84.00 Quite High
INFLAMMATION 5 80.72 Quite High
Increased Venous Pressure Under Development 5 80.68 Quite High
Cancer 35 78.88 Quite High
Hyperinsulinism 11 75.20 Quite High
Chronic Renal Failure 42 69.44 Quite High
Insulin Resistance 23 67.12 Quite High
Malignant Neoplastic Disease 4 59.00 Quite High
Headache 3 58.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
1, characterized by blunted and delayed down-regulation of PRL, IGFBP-1, and TF transcripts, which was not associated with a significant reduction in secretion of PRL or IGFBP-1 proteins.
Negative_regulation (down-regulation) of IGFBP-1
1) Confidence 0.37 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2945765 Disease Relevance 0 Pain Relevance 0
Interestingly, we detected a very rapid reduction in protein release for both IGFBP-1 and PRL in ESCs that preceded any reduction in total concentrations of the mRNAs.
Negative_regulation (reduction) of IGFBP-1
2) Confidence 0.37 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2945765 Disease Relevance 0 Pain Relevance 0
IGF-I SD score, and to a lesser extent IGFBP-III SD score, increased in both groups compared with baseline, whereas GHBP, and to a lesser extent IGFBP-I, decreased.
Negative_regulation (decreased) of IGFBP-I
3) Confidence 0.10 Published 2007 Journal Clinical Endocrinology Section Body Doc Link PMC2366021 Disease Relevance 0.13 Pain Relevance 0.06
Also, Insulin increases IGF-I bioavailability through IGFBP-1 suppression [14,18,19].
Negative_regulation (suppression) of IGFBP-1 associated with bioavailability
4) Confidence 0.09 Published 2007 Journal BMC Endocr Disord Section Body Doc Link PMC2151943 Disease Relevance 0.80 Pain Relevance 0.05
Indomethacin also caused a dose-related inhibition of thromboxane binding (IC50, 3.27 x 10(-4) M).
Negative_regulation (inhibition) of binding
5) Confidence 0.01 Published 1992 Journal Am. J. Physiol. Section Abstract Doc Link 1415690 Disease Relevance 0.21 Pain Relevance 0.20
However, aspirin at a dose of 2.0 x 10(-3) M did not inhibit [3H]SQ 29548 binding.
Negative_regulation (inhibit) of binding associated with aspirin
6) Confidence 0.01 Published 1992 Journal Am. J. Physiol. Section Abstract Doc Link 1415690 Disease Relevance 0.21 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox